NCT04890236View on ClinicalTrials.gov

Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

January 13, 2022

Primary Completion Date

March 20, 2024

Study Completion Date

September 4, 2024

Conditions
Recurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
Interventions
DRUG

Duvelisib

Given PO

BIOLOGICAL

Tisagenlecleucel

Given via infusion

Trial Locations (2)

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

60637

University of Chicago Comprehensive Cancer Center, Chicago

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Secura Bio, Inc.

INDUSTRY

collaborator

Novartis

INDUSTRY

lead

Emory University

OTHER

NCT04890236 - Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study | Biotech Hunter | Biotech Hunter